<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26440212</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2249</ISSN><JournalIssue CitedMedium="Internet"><Volume>183</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Clinical and experimental immunology</Title><ISOAbbreviation>Clin Exp Immunol</ISOAbbreviation></Journal><ArticleTitle>Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies.</ArticleTitle><Pagination><StartPage>326</StartPage><EndPage>340</EndPage><MedlinePgn>326-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cei.12724</ELocationID><Abstract><AbstractText>T lymphocyte hyperactivity and progressive inflammation in systemic lupus erythematosus (SLE) patients results in over-expression of human leucocyte antigen (HLA)-Ib on the surface of lymphocytes. These are shed into the circulation upon inflammation, and may augment production of antibodies promoting pathogenicity of the disease. The objective was to evaluate the association of HLA-Ib (HLA-E, HLA-F and HLA-G) antibodies to the disease activity of SLE. The immunoglobulin (Ig)G/IgM reactivity to HLA-Ib and &#x3b2;2m in the sera of 69 German, 29 Mexican female SLE patients and 17 German female controls was measured by multiplex Luminex(&#xae;)-based flow cytometry. The values were expressed as mean flourescence intensity (MFI). Only the German SLE cohort was analysed in relation to the clinical disease activity. In the controls, anti-HLA-G IgG predominated over other HLA-Ib antibodies, whereas SLE patients had a preponderance of anti-HLA-F IgG over the other HLA-Ib antibodies. The disease activity index, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2000, was reflected only in the levels of anti-HLA-F IgG. Anti-HLA-F IgG with MFI level of 500-1999 was associated with active SLE, whereas inactive SLE revealed higher MFI (&gt;2000). When anti-HLA-F IgG were cross-reactive with other HLA-Ib alleles, their reactivity was reflected in the levels of anti-HLA-E and -G IgG. The prevalence of HLA-F-monospecific antibodies in SLE patients was also associated with the clinical disease activity. Anti-HLA-F IgG is possibly involved in the clearance of HLA-F shed from lymphocytes and inflamed tissues to lessen the disease's severity, and thus emerges as a beneficial immune biomarker. Therefore, anti-HLA-Ib IgG should be considered as a biomarker in standard SLE diagnostics.</AbstractText><CopyrightInformation>&#xa9; 2015 British Society for Immunology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jucaud</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Terasaki Foundation Laboratory, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravindranath</LastName><ForeName>M H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Terasaki Foundation Laboratory, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terasaki</LastName><ForeName>P I</ForeName><Initials>PI</Initials><AffiliationInfo><Affiliation>Terasaki Foundation Laboratory, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales-Buenrostro</LastName><ForeName>L E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Mineral Metabolism, National Institute of Medical Sciences and Nutrition 'Salvador Zubir&#xe1;n', Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiepe</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Charit&#xe9; Universit&#xe4;tsmedizin Berlin, Germany, Humboldt University of Berlin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Charit&#xe9; Universit&#xe4;tsmedizin Berlin, Germany, Humboldt University of Berlin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biesen</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Charit&#xe9; Universit&#xe4;tsmedizin Berlin, Germany, Humboldt University of Berlin.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Exp Immunol</MedlineTA><NlmUniqueID>0057202</NlmUniqueID><ISSNLinking>0009-9104</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000888">Antibodies, Anti-Idiotypic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C056677">HLA-E antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C062341">HLA-F antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059951">HLA-G Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C048844">anti-IgG</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000888" MajorTopicYN="N">Antibodies, Anti-Idiotypic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059951" MajorTopicYN="N">HLA-G Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067251" MajorTopicYN="N">Symptom Flare Up</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA-F</Keyword><Keyword MajorTopicYN="N">HLA-Ib</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">disease activity</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26440212</ArticleId><ArticleId IdType="pmc">PMC4750595</ArticleId><ArticleId IdType="doi">10.1111/cei.12724</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010; 19:119&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304291</ArticleId><ArticleId IdType="pubmed">19946032</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982; 33:167&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">6182766</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of anti&#x2010;nucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55:900&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17139667</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1495&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">12858447</ArticleId></ArticleIdList></Reference><Reference><Citation>Amital H, Shoenfeld Y. Autoimmunity and autoimmune diseases such as systemic lupus erythematosus In: Lahita RG, ed. Systemic lupus erythematosus, 3rd edn San Diego, CA: Academic Press, 1999: 1&#x2013;16.</Citation></Reference><Reference><Citation>Terasaki PI, Mottironi VD, Barnett EV. Cytotoxins in disease autocytotoxins in lupus. N Engl J Med 1970; 283:724&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">5311527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56:481&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1769989</ArticleId><ArticleId IdType="pubmed">12835292</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller&#x2010;Suur C, Larsson PH, Larsson K. T cell activation by organic dust in vitro . Respir Med 2000; 94:821&#x2013;7.]</Citation><ArticleIdList><ArticleId IdType="pubmed">10955760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Saito S, Nakazawa N et al Existence of an immunoglobulin G component of naturally occurring HLA class I antibodies that are not directed against self&#x2010;antigens in human serum. Tissue Antigens 2008; 72:98&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721269</ArticleId></ArticleIdList></Reference><Reference><Citation>De Azevedo Silva J, Addobbati C, Sandrin&#x2010;Garcia P, Crovella S. Systemic lupus erythematosus: old and new susceptibility genes versus clinical manifestations. Curr Genomics 2014; 15:52&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3958959</ArticleId><ArticleId IdType="pubmed">24653663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Bioinformatics Institute. HLA&#x2010;I Alleles
. Available at: http://www.ebi.ac.uk/ipd/imgt/hla (accessed 2013).
</Citation></Reference><Reference><Citation>Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, Charreau B. Expression and release of soluble HLA&#x2010;E is an immunoregulatory feature of endothelial cell activation. Blood 2007; 109:2806&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">17179229</ArticleId></ArticleIdList></Reference><Reference><Citation>Allard M, Oger R, Vignard V et al Serum soluble HLA&#x2010;E in melanoma: a new potential immune&#x2010;related marker in cancer. PLOS ONE 2011; 6:e21118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119680</ArticleId><ArticleId IdType="pubmed">21712991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei XH, Orr HT. Differential expression of HLA&#x2010;E, HLA&#x2010;F, and HLA&#x2010;G transcripts in human tissue. Hum Immunol 1990; 29:131&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">2249951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA&#x2010;G, expressed in human trophoblasts. Science 1990; 248:220&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">2326636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovats S, Librach C, Fisch P et al Expression and possible function of HLA&#x2010;G chain in human cytotrophoblasts In: Chaouat G, Mowbray J, eds. Cellular and molecular biology of the materno&#x2013;fetal relationship. London: INSERM/John Libbey Eurotxt Ltd, 1991:21&#x2013;9.</Citation></Reference><Reference><Citation>Rosado S, Perez&#x2010;Chacon G, Mellor&#x2010;Pita S et al Expression of human leukocyte antigen&#x2010;G in systemic lupus erythematosus. Hum Immunol 2008; 69:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295670</ArticleId></ArticleIdList></Reference><Reference><Citation>Park GM, Lee S, Park B et al Soluble HLA&#x2010;G generated by proteolytic shedding inhibits NK&#x2010;mediated cell lysis. Biochem Biophys Res Commun 2004; 313:606&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahri R, Hirsch F, Josse A et al Soluble HLA&#x2010;G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 2006; 176:1331&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitani A, Sageshima N, Lee N et al Protein expression and peptide binding suggest unique and interacting functional roles for HLA&#x2010;E, F, and G in maternal&#x2010;placental immune recognition. J Immunol 2003; 171:1376&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Geraghty DE. HLA&#x2010;F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol 2003; 171:5264&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">14607927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepin EJ, Bastin JM, Allan DS et al Functional characterization of HLA&#x2010;F and binding of HLA&#x2010;F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30:3552&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11169396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Ishitani A, Geraghty DE. HLA&#x2010;F is a surface marker on activated lymphocytes. Eur J Immunol 2010; 40:2308&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867582</ArticleId><ArticleId IdType="pubmed">20865824</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodridge JP, Burian A, Lee N, Geraghty DE. HLA&#x2010;F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol 2010; 184:6199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777411</ArticleId><ArticleId IdType="pubmed">20483783</ArticleId></ArticleIdList></Reference><Reference><Citation>Morandi F, Cangemi G, Barco S et al Plasma levels of soluble HLA&#x2010;E and HLA&#x2010;F at diagnosis may predict overall survival of neuroblastoma patients. Biomed Res Int 2013; 2013:956878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3856218</ArticleId><ArticleId IdType="pubmed">24350297</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Rahman A, Allen E et al BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxf) 2005; 44:902&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15814577</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee CS, Farewell V, Isenberg DA et al Revised British Isles Lupus Assessment Group 2004 Index. Arthritis Rheum 2006; 54:3300&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17009266</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee CS, Cresswell L, Farewell V et al Numerical scoring for the BILAG&#x2010;2004 index. Rheumatology 2010; 49:1665&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919194</ArticleId><ArticleId IdType="pubmed">20181671</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladmann DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29:288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero&#x2010;Diaz J, Isenberg DA, Ramsey&#x2010;Goldman R. Measures of adult systemic lupus erythematosus. Arthritis Care Res 2011; 63:S37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812450</ArticleId><ArticleId IdType="pubmed">22588757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath MH, Selvan SR, Terasaki PI. Augmentation of anti&#x2010;HLA&#x2010;E antibodies with concomitant HLA&#x2010;Ia reactivity in IFN&#x3b3;&#x2010;treated autologous melanoma cell vaccine recipients. J Immunotoxicol 2012; 9:282&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">22283601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath MH, Pham T, Ozawa M, Terasaki PI. Antibodies to HLA&#x2010;E may account for the non&#x2010;donor&#x2010;specific anti&#x2010;HLA class&#x2010;Ia antibodies in renal and liver transplant recipients. Int Immunol 2012; 24:43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath MH, Terasaki PI, Pham T, Jucaud V, Kawakita S. Therapeutic preparations of IVIg contains naturally occurring anti&#x2010;HLA&#x2010;E Abs that react with HLA&#x2010;Ia (HLA&#x2010;A/&#x2010;B/&#x2010;Cw) alleles. Blood 2013; 121:2013&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath MH, Pham T, El&#x2010;Awar N, Kaneku H, Terasaki PI. Anti&#x2010;HLA&#x2010;E mAb 3D12 mimics MEM&#x2010;E/02 in binding to HLA&#x2010;B and HLA&#x2010;C alleles: Web&#x2010;tools validate the immunogenic epitopes of HLA&#x2010;E recognized by the antibodies. Mol Immunol 2011; 48:423&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">21145594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath MH, Taniguchi M, Chen CW et al HLA&#x2010;E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol Immunol 2010; 47:1121&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">19944464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath MH, Kaneku H, El&#x2010;Awar N, Morales&#x2010;Buenrostro LE, Terasaki PI. Antibodies to HLA&#x2010;E in nonalloimmunized males: pattern of HLA&#x2010;Ia reactivity of anti&#x2010;HLA&#x2010;E&#x2010;positive sera. J Immunol 2010; 185:1935&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">20610644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee CS, Farewell VT, Isenberg DA et al The use of Systemic Lupus Erythematosus Disease Activity Index&#x2010;2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxf) 2011; 50:982&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077910</ArticleId><ArticleId IdType="pubmed">21245073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath MH, Terasaki PI, Kawakita S. Naturally occurring anti&#x2010;HLA&#x2010;E autoantibodies: evidences of HLA&#x2010;Ia reactivity of anti&#x2010;HLA&#x2010;E antibodies, Chapter 35. In: Shoenfeld Y, Gershwin ME, Meroni PI, eds. Autoantibodies. Amsterdam, Netherlands: Elsevier, 2014:1&#x2013;9.</Citation></Reference><Reference><Citation>Wainwright SD, Biro PA, Holmes CH. HLA&#x2010;F is a predominantly empty, intracellular, TAP&#x2010;associated MHC class Ib protein with a restricted expression pattern. J Immunol 2000; 164:319&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">10605026</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresciani A, Pirozzi G, Spera M et al Increased level of serum HLA class I antigens in patients with systemic lupus in patients with systemic lupus erythematosus. Correlation with disease activity. Tissue Antigens 1998; 52:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9714473</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamashvili I, Wolf R, Aultman D et al Soluble HLA&#x2010;I (s&#x2010;HLA&#x2010;I) synthesis in systemic lupus erythematosus. Rheumatol Int 2003; 23:294&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">12879264</ArticleId></ArticleIdList></Reference><Reference><Citation>Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: marker and modulators of an immune response? Immunol Today 1995; 16: 124&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7718084</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabayoyong WB, Zavazava N. Soluble HLA revisited. Leuk Res 2007; 31: 121&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876709</ArticleId><ArticleId IdType="pubmed">16860865</ArticleId></ArticleIdList></Reference><Reference><Citation>Fainardi E, Rizzo R, Melchiorri L et al CSF levels of soluble HLA&#x2010;G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing&#x2010;remitting multiple sclerosis. Mult Scler 2008; 14: 446&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">18208868</ArticleId></ArticleIdList></Reference><Reference><Citation>Campoli M, Ferrone S. Tumour escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 2008; 72: 321&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2729103</ArticleId><ArticleId IdType="pubmed">18700879</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliaresi S, Bresciani A, Ambrosone L et al Increased serum concentrations of soluble HLA&#x2010;class I antigens in hepatitis C virus related mixed cryoglobulinaemia. Ann Rheum Dis 2000; 59:20&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1752989</ArticleId><ArticleId IdType="pubmed">10627422</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Contini P, Setti M et al Soluble human leukocyte antigen&#x2010;G serum levels in patients with acquired immune deficiency syndrome affected by different disease&#x2010;defining conditions before and after antiretroviral treatment. Hum Immunol 2011; 72:712&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21663783</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Contini P, Setti M et al Behavior of non&#x2010;classical soluble HLA class G antigens in human immunodeficiency virus 1&#x2010;infected patients before and after HAART: comparison with classical soluble HLA&#x2010;A, &#x2010;B, &#x2010;C antigens and potential role in immune&#x2010;reconstitution. Clin Immunol 2009; 133:238&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762282</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Contini P, Setti M et al Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus&#x2010;infected patients during antiretroviral therapy: correlation with clinical outcome. Hum Immunol 2007; 68:894&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">18082568</ArticleId></ArticleIdList></Reference><Reference><Citation>Puppo F, Brenci S, Lanza L et al Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. Hum Immunol 1994; 40: 259&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">8002375</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros F, Cabillic F, Toutirais O, Maux AL, Sebti Y, Amiot L. Soluble HLA&#x2010;G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur J Immunol 2008; 38:742&#x2013;9.]</Citation><ArticleIdList><ArticleId IdType="pubmed">18266268</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavazava N, Kr&#xf6;nke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 1996; 2:1005&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8782458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindaman A, Dowden A, Zavazava N. Soluble HLA&#x2010;G molecules induce apoptosis in natural killer cells. Am J Reprod Immunol 2006; 56:68&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16792533</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaggiari GM, Contini P, Dondero A et al Soluble HLA class I induces NK cell apoptosis upon the engagement of killer&#x2010;activating HLA class I receptors through FasL&#x2010;Fas interaction. Blood 2002; 100:4098&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393468</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaggiari GM, Contini P, Carosio R et al Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood 2002; 99:1706&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournel S, Aguerre&#x2010;Girr M, Huc X et al Cutting edge: soluble HLA&#x2010;G1 triggers CD95/CD95 ligand&#x2010;mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000; 164:6100&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10843658</ArticleId></ArticleIdList></Reference><Reference><Citation>Puppo F, Contini P, Ghio M et al Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol 2000; 12:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653855</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagihara M, Shimura T, Yamamoto K et al Clinical significance of serum soluble HLA class I antigens in systemic lupus erythematosus. Tokai J Exp Clin Med 1993; 18:61&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7940609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya N, Shiota M, Yamaguchi A, Ito K. Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:792&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8639176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kippner L, Klint C, Sturfelt G, Bengtsson AA, Eriksson H, Truedsson L. Increased level of soluble HLA class I antigens in systemic lupus erythematosus: correlation with anti&#x2010;DNA antibodies and leukopenia. J Autoimmun 2001; 16:471&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11437496</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>